Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Daré Bioscience Reports First Quarter 2019 Financial Results and Company Update
SAN DIEGO , May 14, 2019 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today reported financial results for the first quarter ended March 31, 2019 and provided a Company update. “The first quarter was an active one for Daré and positioned us well
View HTML
Toggle Summary Daré Bioscience Announces the Publication of a Pharmacokinetics Study of DARE-FRT1, a Potential Therapy for Preterm Birth and Fertility, in Drug Delivery and Translational Research
SAN DIEGO, May 8, 2019 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women’s health innovation, today announced the article entitled “Pharmacokinetics and tolerability of a novel progesterone intravaginal ring in sheep” was published online in the journal Drug Delivery and
View HTML
Toggle Summary Daré Bioscience to Host First Quarter 2019 Financial Results and Company Update Conference Call and Webcast
SAN DIEGO , May 07, 2019 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc.(NASDAQ: DARE), a leader in women’s health innovation, today announced that it will host a conference call and live webcast at 4:30 p.m. Eastern Time on Tuesday, May 14, 2019, to review the Company's financial results for the quarter
View HTML
Toggle Summary Dr. James Simon, Award-Winning Physician, Presents on Ovaprene® as a Promising Novel Non-Hormonal Contraceptive Method in Clinical Development
SAN DIEGO , April 15, 2019 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women’s health innovation, today announced Ovaprene’s inclusion in a presentation to physicians on the latest forms of novel contraception. Ovaprene is Daré’s clinical stage, non-hormonal vaginal ring
View HTML
Toggle Summary Daré Bioscience, Inc. Prices Underwritten Public Offering of Common Stock
SAN DIEGO , April 09, 2019 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), today announced the pricing of an underwritten public offering of 4,575,000 shares of its common stock at a price of $1.10 per share. The company has also granted to the underwriters a 30-day option to acquire an
View HTML
Toggle Summary Daré Bioscience, Inc. Announces Proposed Public Offering of Common Stock
SAN DIEGO , April 08, 2019 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women’s health innovation, today announced that it intends to offer shares of its common stock in an underwritten public offering.  Daré expects to grant to the underwriters of the offering a 30-day
View HTML
Toggle Summary Daré Bioscience Announces Publication of Pharmacokinetics Study of DARE-HRT1, a Potential Hormone Replacement Therapy, in the Journal of Pharmaceutical Sciences
SAN DIEGO , April 08, 2019 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women’s health innovation, today announced the article entitled “Pharmacokinetics and tolerability of a novel 17β-estradiol and progesterone intravaginal ring in sheep” was published online in the
View HTML
Toggle Summary Daré Bioscience, Inc. Regains Listing Compliance on Nasdaq
SAN DIEGO , April 01, 2019 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc.(NASDAQ: DARE), a leader in women’s health innovation, today announced that it received notice from The Nasdaq Stock Market LLC indicating that the Company regained compliance with the minimum bid price requirement in Nasdaq
View HTML
Toggle Summary Daré Bioscience, Inc. to Host Business Update and Full Year 2018 Financial Results Conference Call and Webcast
SAN DIEGO , April 01, 2019 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc.(NASDAQ: DARE), a leader in women’s health innovation, today announced that it will host a conference call and live webcast at 8:30 a.m. Eastern Time on Thursday, April 4, 2019, to provide an update on portfolio strategic corporate
View HTML
Toggle Summary World-renowned Scientist, Described as the Edison of Medicine by Forbes Magazine, Dr. Robert Langer Joins Daré Bioscience Scientific Advisory Board
SAN DIEGO , March 29, 2019 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women’s health innovation, announced that Dr. Robert Langer , co-inventor of Daré‘s novel, segmented intravaginal ring (IVR) drug delivery technology and one of the 10 Institute Professors at the
View HTML